News • Update improves testing

Breast cancer guideline identifies most promising therapies

The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly by the College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO), reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.

Photo
Breast cancer can manifest in a great number of ways. A new guideline aims to better identify the tests most likely to benefit the individual patients.

Image source: © Scientific Animations, Inc.

Globally, more than 1 million women are diagnosed annually with breast cancer, and receptor testing conducted on their biopsies typically shows that approximately eight in 10 of these women have ER-positive breast cancer. Well-performed tests are essential to identify those patients who could benefit from endocrine therapy. And more broadly, hormone receptor status can be valuable for tumor classification and other factors that inform treatment.

The update to this pivotal evidence-based guideline is available in an early online release from the Archives of Pathology & Laboratory Medicine and Journal of Clinical Oncology.

In a notable change, cases with 1-10% of cells staining for ER expression will now be reported as ER-low positive. Pathology reports for these cases should include a recommended comment that acknowledges the more limited data on endocrine responsiveness in this group. Also in such cases, pathologists should report the status of internal controls, with a special comment for specimens that lack internal positive controls.

The new guideline also recommends that laboratories establish specific standard operating procedures to ensure the validity of ER-low positive (1-10%) or ER negative (0 or <1%) results and their interpretation. Correlation of ER staining with the histologic features, and attention to other standard quality control measures, is also recommended, including additional steps to assess unusual or discordant results. The utility of PgR testing continues to be largely prognostic in the ER-positive invasive cancer population, but testing using similar principles to ER testing is still recommended for invasive cancers.

The updated guideline also more clearly recommends that ER be tested in cases of newly diagnosed DCIS (without invasion) to help estimate potential benefit of endocrine therapy to reduce the risk of a future breast cancer event. But, specifically, PgR testing in DCIS is optional. “Like the original guideline, invasive cancers with 1-100% ER staining are considered positive and eligible for endocrine therapy,” Kimberly Allison, MD, FCAP, pathologist and project co-chair explained. “But this update focuses on better assessment of cases with lower levels of ER expression. We wanted to establish guidance to help ensure that the results from hormone receptor testing in women diagnosed with breast cancer are as accurate as possible. This will give physicians and patients more information to guide them when making treatment decisions.”

“The critical point for clinicians is that they need to be aware of and able to discuss with patients the implications of ER-low positive test results,” explained Antonio Wolff, MD, FACP, FASCO, an oncologist representing ASCO and project co-chair. “We now have more standardized recommendations for these cases.” Likewise, patients should be aware of their test results and should be encouraged to discuss decisions to use endocrine therapy with their clinical care team.


Source: College of American Pathologists

15.01.2020

Read all latest stories

Related articles

Photo

Article • Promising approach

Focused ultrasound ablation for treatment of breast tumours

Focused ultrasound (FUS) ablation is an emerging treatment for breast tumours. Its use was highlighted in an October webinar focused on emerging immunotherapy research and breast cancer.

Photo

News • Medication and surgery recommendations

Childhood obesity guidelines: the end of 'watchful waiting'

The American Academy of Pediatrics has issued its first comprehensive guideline on the evaluation and treatment of children and adolescents with obesity, marking an end to previous recommendations.

Photo

News • Making tumours susceptible to chemo

Breast cancer: target protein may hold key to therapy success

A rare variant of a protein present in nearly all human cells may hold the key to improving the effectiveness of breast cancer treatment, according to University of Manchester research.  

Related products

AB-CT · Advanced Breast-CT - nu:view

Mammo CT

AB-CT · Advanced Breast-CT - nu:view

AB-CT – Advanced Breast-CT GmbH
Drtech Europe GmbH · Aidia

Digital Mammography

Drtech Europe GmbH · Aidia

DRTECH EUROPE GmbH
Fujifilm · Amulet Bellus II

Mammo Workstations

Fujifilm · Amulet Bellus II

FUJIFILM Europe GmbH
Fujifilm · Amulet Innovality

Tomosynthesis

Fujifilm · Amulet Innovality

FUJIFILM Europe GmbH
Fujifilm · Amulet Innovality Harmony

Tomosynthesis

Fujifilm · Amulet Innovality Harmony

FUJIFILM Europe GmbH
Subscribe to Newsletter